Currently, four of these ICIs have been approved for NSCLC: nivolumab and pembrolizumab (both anti-PD-1) and atezolizumab and durvalumab (both anti-PD-L1) [28] (Table 1). The gene discussed is CD274; the disease is non-small cell lung carcinoma.